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The inflammatory biomarker YKL-40 decreases stepwise after
exercise stress test
Naja Dam Myginda, Anna Axelssona,b,c, Martin H. Ruwalde, Morten Dalsgaardc,
Rolf Steffensenb, Kasper Iversenc, Julia S. Johansend and Jens Kastrupa
Background Serum YKL-40 is an inflammatory biomarker
associated with disease activity and mortality in diseases
characterized by inflammation such as coronary artery
disease (CAD). Exercise has a positive effect on CAD,
possibly mediated by a decreased inflammatory activity.
This study aimed to compare serial measurements of
serum YKL-40 before and after exercise in patients with
stable CAD versus controls.
Materials and methods Eleven patients with stable CAD
verified by coronary angiography (>70% stenosis) and 11
patients with a computer tomography angiography with no
stenosis or calcification (calcium score= 0) (controls)
performed a standard clinical maximal exercise test. Serum
YKL-40 was measured before exercise, immediately after
exercise, and every hour for 6 h.
Results Cardiovascular risk factors were more prevalent
among the CAD patients compared with the controls. CAD
patients had higher serum concentration of YKL-40 at
baseline compared with controls, median (interquartile
range) 94 (52–151) versus 57 (45–79) μg/l. Serum YKL-40
decreased stepwise after exercise, with a median decrease
of 16 (13–39) μg/l for the CAD patients and 13 (10–22) μg/l
for the controls from baseline to the lowest value.
Thereafter, values increased again toward baseline level.
Time after exercise was a significant factor for decrease in
serum YKL-40 (P< 0.0001), but no difference in YKL-40
decrease over time could be demonstrated between the
groups (P=0.12).
Conclusion Serum YKL-40 is elevated in patients with
documented CAD compared with controls, and it decreases
stepwise after exercise in both groups, indicating an anti-
inflammatory effect of exercise independent of the
presence of coronary atherosclerosis. Cardiovasc
Endocrinol 5:21–27 Copyright © 2016 Wolters Kluwer
Health, Inc. All rights reserved.
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Introduction
Coronary artery disease (CAD) is the most common cause
of death in western countries [1]. Many factors, including
inflammation, are involved in the development of CAD
[2]. Inflammatory processes play a pivotal role in all
stages of the development of both acute and chronic
atherosclerosis – from the initial induction of endothelial
dysfunction and plaque formation to plaque destabiliza-
tion and disruption with superimposed thrombosis lead-
ing to acute myocardial infarction or death [3]. Therefore,
biomarkers with the ability to monitor inflammatory
processes are of incremental importance in CAD.
YKL-40 (also named chitinase 3-like 1 protein, CHI3L1)
is a highly conserved heparin-binding glycoprotein pro-
duced by several cell types of the immune system [4] and
macrophages in atherosclerotic plaques [5,6]. Circulating
YKL-40 is regarded as a non-disease-specific biomarker
of inflammation and tissue remodeling [7–9]. YKL-40
increases with age [8,10–12] and is elevated in diseases
characterized by inflammation, increased extracellular
remodeling, and ongoing fibrosis [4], such as cancer [8],
heart failure [13–15], and ischemic cerebrovascular dis-
ease [16]. YKL-40 is increased in patients with acute
myocardial infarction [17,18] and in patients with stable
CAD [12,14,18–21] and furthermore related to prognosis
[12].YKL-40 has also been found to be a strong predictor
of death independent of diagnosis [22]. A recent study
demonstrated that plasma CHI3L1 (YKL-40) and muscle
CHI3L1 mRNA increase after 1 h of intensive exercise in
healthy participants [23].
Physical inactivity is an important risk factor for CAD,
and increasing evidence suggests that the beneficial
effects of physical activity are mediated partly by redu-
cing vessel wall inflammation [24,25]. The purpose of
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this study was to compare serial measurements of serum
YKL-40 before and after exercise in patients with stable
CAD and angiographic documented coronary artery sten-
osis versus controls referred for suspected CAD, but
found to have no stenosis nor calcification of the coronary
arteries. We hypothesized that serum YKL-40 would
decrease after exercise with a potentially different effect
depending on the degree of coronary artery stenosis.
Materials and methods
Patients referred to the Department of Cardiology,
Hillerød Hospital, Denmark because of stable angina
pectoris were screened for inclusion between March 2010
and March 2012 [26]. Patients with a moderate to high
a-priori risk for CAD underwent direct invasive coronary
angiography (CAG), and the degree of epicardial stenosis
was determined by the invasive cardiologist performing
the CAG. Patients with a low a-priori risk for CAD had a
computer tomography (CT) angiography. The coronary
artery calcium score was obtained from the CT angio-
graphy according to the method described by Agatston
using a threshold of 130 Hounsfield Units (HU) [27]. In
the present study, patients with CAG-documented CAD
(>70% stenosis in minimum 1 epicardial coronary artery)
comprised the CAD patient group, whereas participants
with no stenosis or coronary calcification (calcium
score= 0) served as the control group.
Data were collected via interview with trained health
professionals. A transthoracic echocardiography (Vivid 7;
General Electric, Horten, Norway) was performed before
inclusion, and patients were excluded if the left ven-
tricular ejection fraction was below 50% or in the case of
disease of the heart valves. Furthermore, patients were
excluded if the CAG revealed three-vessel disease or left
main artery stenosis. Further exclusion criteria were as
follows: unstable angina pectoris, previous coronary
artery bypass graft surgery, history of arrhythmia, renal
insufficiency, chronic obstructive pulmonary disease,
inability to perform a bicycle exercise test, or inability to
provide written informed consent.
Bicycle exercise test
A maximal exercise test was performed in both the CAD
patients and the control group. The test was performed
on a bicycle ergometer (eBike Basic; General Electric)
applying a standard clinical protocol. Work load was
gradually increased with 25W every second minute while
patients were monitored with continuous 12-lead ECG
and noninvasive blood pressure measurement every
minute. The exercise test was terminated when patients
reached physical exhaustion or experienced severe chest
pain. The following was registered for all participants:
symptoms, ST-segment changes, maximal work load,
metabolic equivalents, peak blood pressure, and
heart rate.
Blood samples
Peripheral blood samples were drawn a total of eight
times: at baseline right before the exercise test, imme-
diately after test termination, and once every hour until
6 h after the exercise test had terminated. Serum was
extracted and stored at − 80°C until analysis was per-
formed. YKL-40 is stable in blood stored at − 80°C [10].
Serum concentrations of YKL-40 were measured in
November 2013. Samples were determined in duplicates
by a commercial enzyme-linked immunosorbent assay
(Quidel, Santa Clara, California, USA). The detection
limit was 20 μg/l. The intra-assay coefficients of variation
were 5% (at 40 μg/l), 4% (at 104 μg/l), and 4% (at 155 μg/l).
The interassay variation coefficient of variation was less
than 6%.
Ethics
The study was approved by the regional ethics commit-
tee with the reference number H-3-2010.013. All includ-
ed patients gave written consent following oral and
written information.
Statistics
Continuous data with a Gaussian distribution are pre-
sented as mean ± SD. Continuous data with a non-
Gaussian distribution are presented as median (inter-
quartile range). Proportions are presented as number (n)
and percentage (%). Serum YKL-40 was logarithmi-
cally transformed (log10) because of a non-Gaussian
distribution.
An unpaired Student’s t-test was performed for within-
group comparisons of continuous variables with a
Gaussian distribution. A Wilcoxon signed-rank test was
performed on the continuous data with a non-Gaussian
distribution (YKL-40, pack-years, alcohol, and weekly
exercise). Unpaired comparisons of categorical variables
were performed with the χ2-test or Fisher’s exact test, if
any expected value was below 5.
Differences in YKL-40 between groups were tested
using a linear mixed model. Serum YKL-40 was loga-
rithmically transformed (log10) to stabilize the variance.
Statistical analysis was performed using SAS Enterprise
Guide 7.1 (SAS institute Inc., Cary, North Carolina,
USA). A two-sided P-value below 0.05 was considered
statistically significant.
Results
Baseline characteristics
Twelve CAD patients and 12 controls were initially
included. One patient with CAD was excluded because
of missing serum YKL-40 values. One control was
excluded because of very high serum YKL-40 con-
centrations (i.e. 1644 μg/l and > 20 times above normal
levels). Baseline characteristics for the 11 CAD patients
and 11 controls are given in Table 1. Patients with CAD
22 Cardiovascular Endocrinology 2016, Vol 5 No 1
were slightly older than the controls (62.5 vs. 53.5 years),
and a higher proportion of CAD patients were male (91
vs. 27% in the control group). The control group fulfilled
the inclusion and exclusion criteria, but had a normal CT
angiogram. CAD patients were more likely to have dys-
lipidemia and a history of smoking. Among the smokers
in both groups, those with documented CAD had
smoked more pack-years (i.e. 20 cigarettes/day per year).
Furthermore, CAD patients were more often treated with
β blockers and had a lower heart rate at baseline com-
pared with controls. By design, the distribution of cardio-
vascular disease differed between the two groups. Four
(36%) CAD patients had a previous myocardial infarction,
six (55%) had one-vessel disease, and five (45%) had two-
vessel disease. Angiographic stenosis of the right cor-
onary artery was observed in eight patients (72%), left
anterior descending artery in four patients (36%), and in
the left circumflex artery in four (36%) patients.
Bicycle exercise test
The exercise test variables were comparable in the two
groups, with no difference in duration or work load. Peak
heart rate was significantly lower for the CAD patients
compared with the controls. The CAD patients reached a
significantly lower percentage of predicted heart rate
compared with the controls. ECG changes indicating
ischemia were not significantly more frequently seen in
the CAD patients, but angina pectoris was more fre-
quently experienced by the CAD patients compared with
the controls (Table 2). Angina pectoris was the limiting
factor leading to termination of the exercise test in five
CAD-positive patients and none of the controls
(P= 0.04).
Serum YKL-40
Table 3 and Fig. 1 illustrate serum YKL-40 at baseline
right before exercise, immediately after exercise, and
during the first 6 h after exercise, as well as the median
change between each measurement. CAD patients had a
higher level of serum YKL-40 at baseline compared with
controls, with a median (interquartile range) of 94
(52–151) versus 57 (45–79) μg/l. Serum YKL-40 at base-
line was above the 95th percentile for healthy individuals
according to the mean age of the group in two (18%) of
the CAD patients and in one (9%) of the controls. Overall
serum YKL-40 was higher in CAD patients compared
with the controls, but the difference was only borderline
significant 6 h after exercise (P= 0.063). Men had a
higher, although not significant, serum YKL-40 at baseline
compared with women [93 (52–97) vs. 76 (45–79) μg/l,
P= 0.48]. Furthermore, the proportion of patients who
had CAD was also higher among the men compared with
the women (77 vs. 11%).
As illustrated in Figs 1 and 2, serum YKL-40 decreased
stepwise after exercise, reaching the lowest values 2 h
after exercise for the controls [48 (35–63) μg/l] and 4 h
after exercise for the CAD patients [72 (45–119) μg/l].
There was no significant difference between the two
groups with regard to change in serum YKL-40 at any of
the different time points (Table 3). CAD-positive
patients had a median decrease in YKL-40 of 16
(13–39) μg/l, whereas the controls had a median decrease
of 13 μg/l [8,10–21] from baseline to the lowest observed
serum YKL-40 value (P= 0.212). Thereafter, values
increased again toward baseline serum YKL-40 level
(Table 4).
In the mixed model, time after exercise was a significant
factor for the decrease in serum YKL-40 overall
(P< 0.0001), but no difference in YKL-40 decrease over
time could be demonstrated between the two groups
(P= 0.12). There was no difference of the effect of time
on YKL-40 between the groups (P= 0.76), as illustrated
in Fig. 3.
Discussion
In this study, we investigated the effect of exercise on
the inflammatory biomarker serum YKL-40 in patients
with CAD versus controls. We found that serum YKL-40
was higher at baseline for the CAD patients compared
with the controls, and in both groups serum YKL-40
decreased after exercise with a slightly steeper decrease
for the CAD patients than the controls. Time after
exercise was a significant factor for decrease in serum
Table 1 Demographic data of the patients and controls
CAD patients
(N=11)
Controls
(N=11) P-value
Demographics
Age (mean ±SD) (years) 63 (10) 54 (11) 0.052
Males [n (%)] 10 (91) 3 (27) 0.008
Diabetes mellitus [n (%)] 1 (9) 0 1.000
Hypertension [n (%)] 5 (45) 3 (27) 0.66
Dyslipidemia [n (%)] 10 (91) 3 (27) 0.008
Current or former smokers 10 (91) 4 (36) 0.024
Pack-yearsa [median (IQR)]
[n (%)]
30 (25–40) 15 (10–20) 0.004
Alcohol [median (IQR)]
(g/week)
10 (5–12) 6 (0–10) 0.26
Weekly exercise [median
(IQR)] (h)
3 (1–4) 3 (2–5) 0.56
Systolic blood pressure
(mean ±SD) (mmHg)
137 ±21 128 ±13 0.25
Diastolic blood pressure
(mean ±SD) (mmHg)
89 ±15 85 ± 18 0.60
Heart rate (mean ±SD)
(beats/min)
64 ±10 79 ±8 0.001
Previous acute myocardial
infarction [n (%)]
4 (36) 0 (0) *
One-vessel disease [n (%)] 6 (55) 0 (0) *
Two-vessel disease [n (%)] 5 (45) 0 (0) *
Cerebrovascular events [n (%)] 1 (9) 1 (9) 1.00
β Blockers [n (%)] 8 (73) 3 (27) 0.033
CAD, coronary artery disease; eGFR, estimated glomerular filtration rate; IQR,
interquartile range.
aSmokers only, 20 cigarettes/day per year.
*Groups differ by design. P-value for differences between groups was obtained by
the χ2-test (or Fisher’s exact test if any expected value was below 5) for the
categorical variables and by an unpaired Student’s t-test for the continuous
variables. AWilcoxon signed-rank test was performed on the continuous data with
a non-Gaussian distribution (pack-years, alcohol, weekly exercise).
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YKL-40 overall, but we did not observe a difference in
serum YKL-40 decrease over time between the two
groups, indicating that exercise has a beneficial effect on
the inflammatory level independent of atherosclerotic
degree.
Serum YKL-40 is a new inflammatory biomarker, which
potentially could be of interest in monitoring treatment
efficacy, and as a prognostic factor in patients with CAD.
Earlier studies suggest that serum YKL-40 could be a
new biomarker of acute and chronic inflammation in
patients with stable CAD. Circulating serum YKL-40
may reflect the total burden of coronary atherosclerosis or
identify high-risk atherosclerosis with ongoing inflam-
mation and atherosclerotic plaque formation.
In this study, it was interesting that we did not see a
difference between CAD patients and controls with
respect to YKL-40 decrease after exercise. It has already
been established that the formation of fatty streaks and
atherosclerosis begins early in life [28,29] and advanced
atherosclerotic lesions may already appear in young
adulthood [29,30]. Our control group had a mean age of
53.5 years and were therefore likely to have developed
atherosclerosis despite the fact that they did not have
stenosis nor coronary artery calcification on CT angio-
graphy. Inflammation plays a central role in athero-
sclerosis [2], and this could explain why we observed a
Table 2 Exercise test variables
CAD (N=11) Controls (N=11) P-value
Exercise test performance
Duration (mean ±SD) (min) 12 ± 4 13 ± 5 0.39
Maximum strain (mean ±SD) (W) 155 ± 47 177 ± 67 0.37
Maximum work load (METS) (mean ±SD) 7 ± 2 9 ± 3 0.15
Peak systolic blood pressure (mean ±SD) (mmHg) 203 ± 33 203 ± 23 0.99
Peak diastolic blood pressure (mean ±SD) (mmHg) 105 ± 28 94 ± 14 0.31
Peak heart rate (mean ±SD) (beats/min) 136 ± 13 169 ± 15 < 0.001
Predicted heart rate (mean ±SD) (%) 87 ± 12 101 ± 8 0.006
Evidence of ischemia [n (%)]
ST-elevation 1 (9) 0 (0) 1.000
ST-depression 5 (45) 1 (9) 1.000
Angina pectoris 6 (55) 0 (0) 0.012
CAD, coronary artery disease; METS, metabolic equivalents of task.
ST-elevation indicates elevation≥0.1 mV; ST-depression indicates horizontal or down-sloping ST-depressions≥0.1 mV.
Bold values are represented as P<0.05.
A P<0.05 indicates significant differences between the CAD patients and controls.
P-value for differences between groups was obtained by the χ2-test (or Fisher’s exact test if any expected value was below 5) for the categorical variables and by an
unpaired Student’s t-test for the continuous variables.
Table 3 Serum YKL-40 concentrations and changes before and
after exercise test
CAD (n=11) Controls (n=11) P-value
Before exercise test [median
(IQR)] (μg/l)
94 (52–151) 57 (45–79) 0.14
Changea ÷2 (÷14–1) 1 (÷9–5) 0.58
After 0 min [median (IQR)] (μg/l) 93 (60–165) 57 (44–66) 0.09
Changea 12 (7–20) 10 (4–13) 0.41
After 1 h [median (IQR)] (μg/l) 85 (48–158) 51 (41–73) 0.11
Changea 8 (÷3–16) 3 (0–6) 0.41
After 2 h [median (IQR)] (μg/l) 72 (51–146) 48 (35–63) 0.11
Changea ÷2 (÷8–6) 1 (÷1–6) 0.45
After 3 h [median (IQR)] (μg/l) 76 (56–141) 48 (30–30) 0.16
Changea 3 (÷3–9) ÷2 (÷9–5) 0.21
After 4 h [median (IQR)] (μg/l) 72 (45–119) 52 (38–66) 0.16
Changea ÷4 (÷10–7) ÷2 (÷5–3) 0.78
After 5 h [median (IQR)] (μg/l) 74 (49–132) 58 (42–69) 0.12
Changea ÷5 (÷8–0) ÷2 (÷3–1) 0.62
After 6 h [median (IQR)] (μg/l) 89 (61–128) 55 (41–69) 0.06
Maximum decrease [median
(IQR)] (μg/l)
÷16 (13–39) ÷13 (10–22) 0.21
Serum YKL-40 is given in μg/l.
CAD, coronary artery disease; IQR, interquartile range.
aChange between samples above and below.
÷ indicates decrease in values.
P-value for differences between groups was obtained by a Wilcoxon signed-rank
test because of non-Gaussian distribution.
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decrease in both groups and why exercise had a positive
effect on inflammation in both CAD patients and
controls.
A recent study demonstrated increasing plasma YKL-40
and muscle tissue YKL-40 mRNA values after 1 h of
intensive exercise [23]. Another recent study showed that
marathon running increased the levels of circulating
YKL-40 by 56% [31]. However, yet another study
observed no effect on serum YKL-40 after physical
exercise [32]. It is possible that a higher intensity and/or a
longer duration are necessary for induction of increases
in circulating YKL-40 levels in response to exercise.
However, none of the mentioned studies considered
the changes in YKL-40 after exercise as did the
present study.
Inflammation is an important factor in the pathogenesis
of atherosclerosis, and several markers of inflammation
have been associated with an increased risk of cardio-
vascular events. Physical activity may lower the risk for
CAD by decreasing inflammation. Other studies have
shown that exercise decreases inflammation by decreas-
ing inflammatory markers such as C-reactive protein and
VCAM-1 [33]. In a study of 177 inactive patients and
overweight patients, a single measurement of the
inflammatory marker high-sensitivity C-reactive protein
was inversely correlated to physical fitness independent
of other cardiovascular risk factors. The authors conclude
that this indicates the beneficial effects of physical
activity on inflammation [34].
Strengths and limitations
To our knowledge, this is the first study to compare serial
measurements of serum YKL-40 after exercise in a
population of patients with documented CAD and a
control group with suspected stable angina but with
normal coronary arteries. The cohort was consecutively
collected and was representative of CAD patients. Some
important limitations in this study need to be addressed.
First of all, there were a limited number of participants,
which has an impact on the possible generalizability of
the results. The borderline significant difference in age
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Individual changes in serum YKL-40 (μg/l) after exercise test. Serum YKL-40 was measured at baseline, immediately after exercise, and once every
hour for 6 h after exercise. The lines represent each individual. (a) CAD patients; (b) controls. The horizontal dotted line represent 95th percentile
(YKL-40 concentration) according to the mean age for each group [10]. CAD, coronary artery disease.
Table 4 Research on YKL-40 in cardiovascular disease
Known facts about YKL-40 and CAD Findings from this research
YKL-40 is an inflammatory biomarker YKL-40 decreases after exercise, indicating a beneficial effect of exercise on the
inflammatory level
YKL-40 increases with age [8,10–12] Time after exercise is significant for the decrease in YKL-40
YKL-40 is increased in patients with CAD [12,14,18–21]
In patients with CAD, YKL-40 is related to prognosis [12] and a predictor of
death [22]
CAD, coronary artery disease.
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between the two groups represents a possible con-
founder, as age is known to be associated with serum
concentrations of YKL-40. The choice of the control
group can also be discussed, as these were referred
because of stable angina pectoris and possible CAD, but
were found to have no stenosis nor calcification on CT
angiography. Ideally, the control group should be free
from symptoms, and it is possible that the control group
could represent a population with stable microvascular
disease causing them to have angina pectoris.
Furthermore, coronary artery pathology was assessed
with different methods in the CAD patients and the
controls, because of different a-priori risk for CAD. This,
however, represents a daily clinical practice scenario, and
a CT angiography has a high negative predictive value
and therefore it is unlikely that the difference method
has affected the results.
Conclusion
Serum YKL-40 was higher in CAD patients compared
with controls, but both groups experienced declining
values after exercise, indicating that exercise has an anti-
inflammatory effect independent of the degree of the
atherosclerotic burden.
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